Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?

BACKGROUND. Borderline resectable pancreatic cancer is best treated by multimodality therapy. FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, and leucovorin) tripled the response rate and significantly increased median survival for patients with advanced pancreatic cancer and shows promise for...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Christians, Kathleen K., Tsai, Susan, Mahmoud, Anna, Ritch, Paul, Thomas, James P., Wiebe, Lauren, Kelly, Tracy, Erickson, Beth, Wang, Huamin, Evans, Douglas B., George, Ben
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2014
Assuntos:
Gastrointestinal Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3958454/
https://ncbi.nlm.nih.gov/pubmed/24569947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0273
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares